Understanding Prozac: What It Is, How It Works, and What It Treats

Fluoxetine, commonly known by its brand name Prozac, is a widely recognized medication approved by the Food and Drug Administration (FDA). It plays a crucial role in treating a range of psychological conditions, demonstrating its effectiveness in managing major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, bulimia nervosa, binge eating disorder, premenstrual dysphoric disorder (PMDD), and bipolar depression. In some instances, it’s also used in conjunction with olanzapine to treat depression that hasn’t responded to other treatments. Prozac’s mechanism of action centers on inhibiting the reuptake of serotonin in the brain, a process that helps to regulate mood and emotions.

This article aims to provide a comprehensive overview of Prozac. We will explore its various uses, both FDA-approved and off-label, delve into how it works in the brain, discuss dosage guidelines, potential side effects, contraindications, and considerations for monitoring and managing its use. This information is vital for anyone seeking to understand Prozac, whether for personal knowledge, academic purposes, or professional healthcare practice.

Alt text: A photograph displaying Fluoxetine capsules alongside an opened blister pack, emphasizing the medication’s availability and common packaging.

Prozac Uses: FDA-Approved and Off-Label

Prozac, or fluoxetine, is a versatile medication with several FDA-approved applications, as well as uses that are considered “off-label.” Understanding these distinctions is crucial for appreciating the full scope of Prozac’s therapeutic potential.

FDA-Approved Indications

Fluoxetine has gained FDA approval for treating several conditions across different age groups. These include:

• Major Depressive Disorder (MDD): For both adults and children aged 8 years and older, Prozac is approved to treat MDD, a condition characterized by persistent sadness and loss of interest in daily activities.
• Obsessive-Compulsive Disorder (OCD): Prozac is indicated for the treatment of OCD in adults and children aged 7 years and older. OCD involves recurrent, unwanted thoughts (obsessions) and repetitive behaviors (compulsions).
• Panic Disorder: Adults experiencing panic disorder, with or without agoraphobia (fear of places or situations that might cause panic), can be treated with Prozac. Panic disorder is marked by sudden episodes of intense fear that trigger severe physical reactions.
• Bulimia Nervosa: Prozac is FDA-approved for the treatment of bulimia nervosa, an eating disorder characterized by a cycle of binge eating and compensatory behaviors like purging. The American Psychiatric Association guidelines recommend fluoxetine as a first-line medication, often in conjunction with Cognitive Behavioral Therapy (CBT), for bulimia nervosa.
• Bipolar I Disorder – Depressive Episodes: When used as an adjunct to olanzapine, Prozac is approved for treating depressive episodes associated with Bipolar I disorder, a condition characterized by episodes of mania and depression.
• Treatment-Resistant Depression (TRD): In combination with olanzapine, Prozac is also approved for treating cases of major depressive disorder that have not responded adequately to other antidepressant treatments.

Off-Label Uses of Prozac

Beyond its FDA-approved indications, Prozac is also used “off-label” to treat other conditions. Off-label use means that the medication is being used in a way that is not specifically approved by the FDA, but is still considered a legitimate and evidence-based treatment option in certain circumstances. Some of these off-label uses for fluoxetine include:

• Binge Eating Disorder: While not formally FDA-approved for this specific eating disorder, Prozac is sometimes used to help manage binge eating disorder, characterized by episodes of consuming large quantities of food, often in secret, accompanied by feelings of guilt or shame.
• Social Anxiety Disorder: Prozac may be prescribed to treat social anxiety disorder, which involves intense fear of social situations where one might be scrutinized by others.
• Premenstrual Dysphoric Disorder (PMDD): PMDD is a severe form of premenstrual syndrome (PMS) that includes mood swings, irritability, depression, and anxiety in the week or two before menstruation. Prozac can be effective in alleviating these symptoms.
• Borderline Personality Disorder (BPD): Although not a primary treatment, Prozac may be used to help manage certain symptoms associated with borderline personality disorder, such as mood instability and impulsivity.
• Raynaud Phenomenon: Prozac has been explored for treating Raynaud phenomenon, a condition that causes reduced blood flow to the fingers and toes in response to cold or stress.
• Selective Mutism: In some cases, Prozac is used to treat selective mutism, an anxiety disorder where a person who is normally capable of speech does not speak in specific situations or to specific people.
• Post-Traumatic Stress Disorder (PTSD): While other SSRIs are more commonly used and FDA-approved for PTSD, the American Psychological Association endorses fluoxetine as a treatment option for post-traumatic stress disorder, a condition that can develop after experiencing or witnessing a traumatic event.

It is important to note that while off-label uses are not FDA-approved, they are often based on clinical evidence and professional consensus. Decisions regarding off-label use are made by healthcare providers considering the individual patient’s needs and the available scientific literature.

How Prozac Works: Mechanism of Action

Prozac belongs to a class of antidepressants known as Selective Serotonin Reuptake Inhibitors (SSRIs). To understand how Prozac works, it’s essential to grasp the role of serotonin in the brain and how SSRIs affect it.

The Role of Serotonin

Serotonin is a neurotransmitter, a chemical messenger that transmits signals between nerve cells (neurons) in the brain. It plays a significant role in regulating various bodily functions and psychological processes, including:

• Mood: Serotonin is often referred to as the “feel-good” neurotransmitter because it contributes to feelings of well-being, happiness, and calmness. Imbalances in serotonin levels are linked to mood disorders like depression and anxiety.
• Sleep: Serotonin is involved in regulating the sleep-wake cycle. It is a precursor to melatonin, a hormone that promotes sleep.
• Appetite: Serotonin helps regulate appetite and digestion. It can influence feelings of fullness and satisfaction after eating.
• Social Behavior: Serotonin influences social behavior, including impulsivity, aggression, and social interactions.
• Other Functions: Serotonin also plays roles in memory, learning, body temperature regulation, and even blood clotting.

In individuals with depression and certain other psychiatric conditions, it’s believed that serotonin levels or serotonin activity in the brain may be reduced or imbalanced.

Prozac’s Action: Blocking Serotonin Reuptake

Prozac’s primary mechanism of action is to selectively inhibit the reuptake of serotonin in the brain. Here’s how this process works:

1. Serotonin Release: When a nerve signal is transmitted, neurons release serotonin into the synapse, the gap between nerve cells.
2. Serotonin Action: Serotonin then binds to receptors on the receiving neuron, transmitting the signal and exerting its effects.
3. Reuptake Process: After serotonin has done its job, it is normally reabsorbed back into the presynaptic neuron that released it. This reabsorption is called “reuptake,” and it’s carried out by a protein called the serotonin transporter. This process clears serotonin from the synapse and stops its signal transmission.
4. Prozac’s Inhibition: Prozac blocks the serotonin transporter protein. By doing so, it prevents the reuptake of serotonin.
5. Increased Serotonin Availability: As a result of Prozac blocking reuptake, more serotonin remains in the synapse for a longer period. This increases the availability of serotonin to bind to receptors on receiving neurons, enhancing serotonin neurotransmission.

Alt text: A simplified diagram showing how reuptake inhibitors, like Prozac, block the reuptake of neurotransmitters in the synapse, increasing their availability.

By increasing serotonin levels in the synapse, Prozac helps to alleviate symptoms of depression, OCD, panic disorder, and other conditions where serotonin is believed to play a role. It’s important to note that Prozac, like other SSRIs, primarily targets serotonin and has minimal impact on other neurotransmitters like norepinephrine. This selectivity is why it’s called a “selective” serotonin reuptake inhibitor.

Onset of Action and Pharmacokinetics

It’s crucial to understand that Prozac doesn’t work immediately. Due to its mechanism and the complex way the brain adapts to changes in neurotransmitter levels, the antidepressant effects of Prozac typically emerge gradually, usually within 2 to 4 weeks of starting treatment.

Prozac has a long half-life, ranging from 2 to 4 days, and its active metabolite, norfluoxetine, has an even longer half-life of 7 to 9 days. This means that Prozac and its effects can persist in the body for several weeks even after discontinuation. This long half-life has implications for dosing, switching medications, and managing potential withdrawal effects.

Pharmacokinetics in Detail:

• Absorption: Prozac is well-absorbed after oral administration, with peak plasma concentrations reached within 6 to 8 hours. Its bioavailability is high, ranging from 70% to 90%. Food may slightly delay absorption but doesn’t significantly affect the total amount absorbed.
• Distribution: Prozac is highly protein-bound (about 94.5%) in plasma, primarily to albumin and alpha-1 glycoprotein. It readily crosses the blood-brain barrier, achieving higher concentrations in the brain compared to plasma. It has a large volume of distribution, indicating it distributes widely into tissues.
• Metabolism: Prozac is metabolized in the liver, primarily by the cytochrome P450 enzyme CYP2D6, into its active metabolite norfluoxetine. This metabolic pathway is important because Prozac can interact with other drugs metabolized by CYP2D6. Genetic variations in CYP2D6 activity can affect how individuals metabolize Prozac.
• Elimination: Prozac and norfluoxetine are eliminated slowly from the body due to their long half-lives. Only a small percentage of the administered dose is excreted unchanged in the urine. The long elimination half-life means that it takes several weeks for Prozac to be fully eliminated from the body after stopping the medication.

Prozac Administration and Dosage

Proper administration and dosage of Prozac are essential for its effectiveness and safety. Prozac is available in various oral formulations and strengths, allowing for flexible dosing based on individual patient needs and the condition being treated.

Available Dosage Forms and Strengths

Prozac is exclusively available in oral formulations, which include:

• Oral Solution: 20 mg/5 mL
• Tablets: 10 mg, 20 mg, 60 mg
• Capsules: 10 mg, 20 mg, 40 mg
• Delayed-Release Capsules: 90 mg (designed for once-weekly dosing)
• Fixed-Dose Combination with Olanzapine: Capsules containing olanzapine 6 mg and fluoxetine 25 mg (marketed as Symbyax, used for bipolar depression and treatment-resistant depression)

Prozac is typically taken once a day, either in the morning or evening. However, the delayed-release 90 mg capsules are designed for once-weekly administration. The choice of formulation and dosing frequency depends on the patient’s condition, tolerability, and prescriber’s recommendations.

Adult Dosing Guidelines

Dosage for Prozac varies depending on the condition being treated. Common starting and maintenance doses for adults are as follows:

• Major Depressive Disorder (MDD):
  • Starting dose: 20 mg daily
  • Maximum recommended dose: 80 mg daily
• Obsessive-Compulsive Disorder (OCD):
  • Starting dose: 20 mg daily
  • Typical maintenance dose: 20 to 60 mg daily
• Bulimia Nervosa:
  • Recommended dose: 60 mg daily (typically after psychotherapy has been tried for 6 weeks with minimal response)
• Panic Disorder:
  • Starting dose: 10 mg daily
  • Dose increase: May be increased to 20 mg daily after one week
  • Maximum recommended dose: 60 mg daily

Dosage adjustments are made based on individual patient response and tolerability. Some individuals may respond to lower doses (e.g., 5 mg or 10 mg), while others may require higher doses within the recommended range.

Special Patient Populations

Dosage adjustments may be necessary for certain patient populations:

• Hepatic Impairment: Patients with liver cirrhosis may have reduced clearance of fluoxetine and norfluoxetine, leading to increased half-lives. Lower or less frequent dosing is recommended in these patients. Caution is advised when using Prozac in patients with any condition affecting liver metabolism.
• Renal Impairment: No routine dose adjustment is generally required for patients with renal impairment. Studies suggest that once-weekly Prozac may be a feasible option for hemodialysis patients.
• Pregnancy: Prozac is categorized as Pregnancy Category C. Neonates exposed to SSRIs, including fluoxetine, in the late third trimester may develop complications. Clinicians may consider tapering Prozac in the third trimester. Careful risk-benefit assessment is necessary when considering Prozac use during pregnancy.
• Breastfeeding: Prozac is excreted in breast milk, and breastfeeding while taking Prozac is generally not recommended. If Prozac is used during pregnancy, experts often advise against changing medications during breastfeeding unless there are concerns about infant adverse effects. Infants should be monitored for behavioral side effects.
• Pediatric Patients: Prozac is FDA-approved for MDD and OCD in children and adolescents. The starting dose for children is typically 10 mg daily. Weight should be monitored in pediatric patients as decreased weight gain can occur. Fluoxetine is often considered a first-line antidepressant for youth due to its favorable risk-benefit profile compared to other antidepressants in this age group.
• Older Patients: Prozac is effective for MDD in older adults. A lower starting dose of 10 mg daily is usually recommended for older patients, which can be increased to 20 mg as tolerated.

Prozac Side Effects and Drug Interactions

Like all medications, Prozac can cause side effects and interact with other drugs. Understanding these aspects is crucial for safe and effective use.

Common Side Effects

Prozac can cause a range of side effects, although not everyone experiences them, and many side effects are mild and temporary. Common side effects reported by adults include:

• Gastrointestinal Issues: Nausea, diarrhea, anorexia (loss of appetite), dry mouth.
• Central Nervous System Effects: Insomnia, headache, drowsiness, anxiety, nervousness, yawning, agitation.
• Sexual Dysfunction: Decreased libido, erectile dysfunction, delayed ejaculation (anorgasmia and ejaculation latency).
• Other Side Effects: Bruising, seizures (rarely), bleeding (rarely), hyperhidrosis (excessive sweating), induction of mania, rare activation of suicidal ideation and behavior (especially in teenagers and young adults), weight gain or loss, muscle weakness, tremors, pharyngitis (sore throat).

Some side effects, like anxiety, insomnia, and agitation, may be related to Prozac’s 5-HT2C receptor antagonism. Patients may even experience panic attacks initially. It’s important to educate patients about potential side effects and reassure them that many are temporary and dose-dependent.

Most side effects tend to diminish over time as the body adjusts to the medication. Clinicians should monitor for agitation or activation, which could indicate a bipolar state and necessitate the addition of a mood stabilizer or antipsychotic. If insomnia is a problem, dosing Prozac earlier in the day may help. Dose reduction can be considered if side effects are distressing. If side effects persist and are bothersome, switching to a different antidepressant may be necessary after a few weeks.

Rare but serious side effects reported with Prozac include:

• Reversible Cerebral Vasoconstriction Syndrome: Can present with severe headache.
• Chorea: Involuntary, jerky movements (rare case report).
• Rabbit Syndrome: Rapid, fine, rhythmic mouth movements (rare case report, more common with antipsychotics).
• Stevens-Johnson Syndrome: A severe skin reaction (rare).

If side effects become problematic, strategies to manage them include:

• Insomnia: Consider trazodone, mirtazapine, or a hypnotic.
• Agitation or Gastrointestinal Issues: Mirtazapine may be helpful.
• Anxiety: Benzodiazepines may be used short-term.
• Sexual Dysfunction: Bupropion or a phosphodiesterase inhibitor (like sildenafil) may be options. Bupropion may also help with cognitive slowing or apathy.

Drug-Drug Interactions

Prozac can interact with numerous other medications, primarily because it inhibits the CYP2D6 enzyme, which is involved in the metabolism of many drugs. Significant drug interactions include:

• Tricyclic Antidepressants (TCAs): Prozac can increase TCA levels, potentially requiring TCA dose adjustment.
• Antipsychotics: Prozac can increase levels of haloperidol and clozapine. Co-administration of aripiprazole and fluoxetine may increase the risk of QT prolongation.
• Antiarrhythmic Medications: Concurrent use with Class 1A and Class III antiarrhythmics can increase the QT interval.
• Benzodiazepines: Prozac can increase plasma concentrations of alprazolam and diazepam, potentially leading to increased sedation.
• Warfarin: Prozac has a relatively high risk of interaction with warfarin, increasing bleeding risk. PT/INR monitoring is essential.
• NSAIDs/Aspirin: Concurrent use increases the risk of upper gastrointestinal bleeding.
• Anticonvulsants: Prozac can increase plasma concentrations of phenytoin and carbamazepine, requiring therapeutic drug monitoring (TDM).
• Serotonergic Agents: Combining Prozac with other serotonergic drugs (e.g., triptans, TCAs, fentanyl, lithium, tramadol, St. John’s Wort) increases the risk of serotonin syndrome.

Prozac Contraindications, Warnings, and Precautions

Certain conditions and situations contraindicate the use of Prozac, while others require caution and monitoring.

Contraindications

Prozac is contraindicated in the following situations:

• Hypersensitivity: Known allergy to fluoxetine or any component of its formulation.
• Monoamine Oxidase Inhibitors (MAOIs): Concurrent use with MAOIs or within 2 weeks of discontinuing an MAOI due to the risk of serotonin syndrome.
• Linezolid: Never initiate Prozac in a patient receiving linezolid (an antibiotic with MAOI properties).
• Pimozide or Thioridazine: Co-administration with pimozide or thioridazine due to the risk of QT prolongation.

Prozac should be used with caution in patients with a history of seizures or older adults.

Boxed Warning

Prozac carries a boxed warning from the FDA regarding the increased risk of suicidal ideation and behavior in children, adolescents, and young adults (18-24 years old) during initial treatment. Patients, families, and caregivers should be educated about this risk and closely monitor for any behavioral changes, especially in the first two months of treatment or when doses are adjusted.

Warnings and Precautions

Additional warnings and precautions associated with Prozac use include:

• Pregnancy: Prozac is not generally recommended during pregnancy, especially in the first and third trimesters, due to potential risks to the fetus and newborn. A careful risk-benefit assessment is necessary if treatment is considered essential during pregnancy.
• Electroconvulsive Therapy (ECT): Seizures have been reported in patients receiving ECT while on Prozac. Caution is advised in patients undergoing ECT.
• Allergic Reactions and Rash: If a rash or allergic reaction develops, Prozac should be discontinued. Stevens-Johnson syndrome has been reported with fluoxetine.
• Activation of Mania/Hypomania: Prozac can trigger manic or hypomanic episodes in individuals with bipolar disorder. Patients should be screened for bipolar disorder before starting Prozac, and mood should be monitored during treatment.
• Anxiety and Insomnia: Prozac may initially increase anxiety and insomnia in some patients.
• Angle-Closure Glaucoma: Prozac may cause angle-closure glaucoma. Intraocular pressure should be monitored in patients with a history of glaucoma.
• Hyponatremia: In rare cases, Prozac can cause hyponatremia (low sodium levels) due to syndrome of inappropriate antidiuretic hormone (SIADH).
• QT Prolongation: Prozac can prolong the QT interval, potentially increasing the risk of torsade de pointes, a dangerous heart rhythm. Use with caution in patients with risk factors for QT prolongation.
• Cognitive Impairment: Prozac may impair cognitive function and motor skills. Patients should be cautioned about tasks requiring alertness, such as operating machinery or driving, until they know how Prozac affects them. Paradoxically, some studies suggest Prozac may improve cognition in dementia patients.
• Sexual Dysfunction: As mentioned earlier, sexual side effects are common with Prozac and other SSRIs.

Monitoring and Management

Regular monitoring is important when using Prozac to assess effectiveness, manage side effects, and ensure safety.

Monitoring Parameters

Recommended monitoring includes:

• Depression and Suicidal Risk Assessment: Especially at the beginning of therapy and with dose changes. Utilize tools like the PHQ-9 (Patient Health Questionnaire-9) and HAM-D/HDRS (Hamilton Depression Rating Scale).
• Anxiety/Panic Attacks, Social Functioning, Mania/Mood Lability: Monitor for changes in these areas.
• Serotonin Syndrome: Be vigilant for signs and symptoms of serotonin syndrome, especially when starting or increasing doses or combining with other serotonergic agents.
• Routine Laboratory Tests: Not routinely needed for healthy individuals. However, in older adults and specific populations, consider blood glucose and liver function tests.
• ECG: May be considered for patients with risk factors for QT prolongation or ventricular arrhythmias.
• Pediatric Patients: Monitor height and weight periodically in children and adolescents.

Washout Period

Due to Prozac’s long half-life, a washout period is necessary when switching to certain other medications, particularly MAOIs. When switching from Prozac to an MAOI, a washout period of at least 5 weeks is generally recommended to avoid serotonin syndrome.

For interventional spine and pain procedures, the American Society of Regional Anesthesia (ASRA) suggests a washout period of approximately 5 weeks before procedures due to the increased bleeding risk associated with Prozac.

Prozac Overdose and Toxicity

Prozac overdose is rarely lethal when taken alone. However, overdose can lead to significant symptoms and requires medical management.

Symptoms of Overdose

Symptoms of Prozac overdose may include:

• Nausea, vomiting
• Seizures
• Cardiovascular effects (e.g., QT prolongation, arrhythmias)
• Serotonin syndrome (in severe cases or when combined with other serotonergic drugs)
• Central nervous system depression (with very high doses or co-ingestion of alcohol or other CNS depressants)

Management of Overdose

Management of Prozac overdose is primarily supportive and may include:

• Airway Protection: Ensuring adequate airway and breathing.
• Serial ECGs: Monitoring for cardiotoxicity.
• Benzodiazepines: For sedation and seizure control.
• GI Decontamination: Activated charcoal may be considered if the overdose is recent and the patient is alert and able to protect their airway.
• Serotonin Syndrome Treatment: If serotonin syndrome develops, cyproheptadine (a serotonin antagonist) may be used.

Enhancing Healthcare Team Outcomes

Effective Prozac therapy often requires a collaborative interprofessional healthcare team approach. This team may include physicians (primary care, psychiatrists), advanced practice practitioners (NPs, PAs), pharmacists, nurses, and mental health professionals.

Key roles of team members:

• Prescribers (Physicians, APPs): Diagnose, prescribe, monitor treatment, adjust doses, manage side effects, consider drug interactions, educate patients.
• Pharmacists: Verify dosing, check for drug interactions, counsel patients on medication use, potential side effects, and storage.
• Nurses (especially psychiatric nurses): Monitor patients for therapeutic effects and side effects, assess mental status and suicidal ideation, provide patient education and support, ensure medication adherence.
• Mental Health Professionals (Therapists, Counselors): Provide psychotherapy (e.g., CBT), monitor patient progress, communicate with prescribers about patient status and response to treatment.

Interprofessional collaboration is crucial for:

• Optimizing treatment: Ensuring appropriate diagnosis, medication selection, and dosing.
• Minimizing adverse effects: Proactively monitoring for and managing side effects and drug interactions.
• Improving patient safety: Reducing risks associated with overdose, serotonin syndrome, and suicidal ideation.
• Enhancing patient education and adherence: Providing clear and consistent information to patients and families.
• Achieving optimal patient outcomes: Improving symptom control, functional outcomes, and quality of life.

Regular communication and shared decision-making among team members are essential for successful Prozac therapy and positive patient outcomes.

Healthcare team discussing patient care

In conclusion, Prozac is a valuable medication for treating a range of psychiatric conditions. Understanding its mechanism of action, uses, administration, side effects, and safety considerations is critical for healthcare professionals and patients alike. Effective use of Prozac requires careful assessment, appropriate prescribing, diligent monitoring, and a collaborative healthcare team approach to optimize patient outcomes and minimize potential risks.

Review Questions (For self-assessment and continuing education, as in the original article)

(Note: As per instructions, I am not including the review questions here to maintain focus on the article content itself. The original article includes review questions for self-assessment).

References

(Note: All references from the original article are retained to ensure accuracy and facilitate further reading. These are presented in markdown format as requested.)

1.Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. Cochrane Database Syst Rev. 2019 Apr 12;4(4):CD012680. [PMC free article: PMC6459769] [PubMed: 30977111]

2.Dhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. Biochimie. 2019 Jun;161:73-79. [PubMed: 30953672]

3.Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol. 2019 Mar 21;21(4):18. [PubMed: 30895388]

4.Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, Golden N, Guarda A, Jackson-Triche M, Manzo L, Mascolo M, Pierce K, Riddle M, Seritan A, Uniacke B, Zucker N, Yager J, Craig TJ, Hong SH, Medicus J. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. Am J Psychiatry. 2023 Feb 01;180(2):167-171. [PubMed: 36722117]

5.Li X, Li J, Li X, Wang J, Dai H, Wang J. Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review. Medicine (Baltimore). 2019 Feb;98(7):e14481. [PMC free article: PMC6407935] [PubMed: 30762772]

6.Slee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-777. [PubMed: 30712879]

7.Martin A, Naunton M, Kosari S, Peterson G, Thomas J, Christenson JK. Treatment Guidelines for PTSD: A Systematic Review. J Clin Med. 2021 Sep 15;10(18) [PMC free article: PMC8471692] [PubMed: 34575284]

8.Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000 Jan;85(1):11-28. [PubMed: 10674711]

9.Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early Interv Psychiatry. 2019 Oct;13(5):1032-1049. [PubMed: 30690898]

10.Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 08;92:109-117. [PubMed: 30611836]

11.Delavenne X, Magnin M, Basset T, Piot M, Mallouk N, Ressnikoff D, Garcin A, Laporte S, Garnier P, Mismetti P. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundam Clin Pharmacol. 2013 Dec;27(6):683-9. [PubMed: 23413998]

12.Deodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021 Jan 23;13(2) [PMC free article: PMC7912198] [PubMed: 33498694]

13.Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. [PubMed: 25721705]

14.Andrade C. Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning. J Clin Psychiatry. 2022 Aug 01;83(4) [PubMed: 35921503]

15.Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs. 2001;61(15):2221-8; discussion 2229-30. [PubMed: 11772132]

16.Kauffman KM, Dolata J, Figueroa M, Gunzler D, Huml A, Pencak J, Sajatovic M, Sehgal AR. Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial. Kidney Med. 2022 Mar;4(3):100413. [PMC free article: PMC8978139] [PubMed: 35386606]

17.Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P., Danish Psychiatric Society. Danish Society of Obstetrics and Gynecology. Danish Paediatric Society. Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta Psychiatr Scand Suppl. 2015;(445):1-28. [PubMed: 26344706]

18.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Fluoxetine. [PubMed: 30000245]

19.Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 2023 May;62(5):479-502. [PubMed: 36273673]

20.Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020 Jun;19(2):214-232. [PMC free article: PMC7215080] [PubMed: 32394557]

21.Gutsmiedl K, Krause M, Bighelli I, Schneider-Thoma J, Leucht S. How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. BMC Psychiatry. 2020 Mar 04;20(1):102. [PMC free article: PMC7057600] [PubMed: 32131786]

22.Mullen S. Major depressive disorder in children and adolescents. Ment Health Clin. 2018 Nov;8(6):275-283. [PMC free article: PMC6213890] [PubMed: 30397569]

23.Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. Br J Clin Pharmacol. 2018 Dec;84(12):2704-2715. [PMC free article: PMC6255988] [PubMed: 30248178]

24.Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017 Aug 09;19(9):63. [PMC free article: PMC5548844] [PubMed: 28791566]

25.Manning T, Bartow C, Dunlap M, Kiehl R, Kneale H, Walker A. Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine. J Acad Consult Liaison Psychiatry. 2021 Nov-Dec;62(6):634-644. [PubMed: 34371244]

26.Laban T, Larroche C, Comparon C, Dhôte R, Degos B. Fluoxetine-induced chorea. Rev Neurol (Paris). 2021 Oct;177(8):1010-1011. [PubMed: 34148736]

27.Naguy A, Moodliar-Rensburg S, Elsori DH, Alamiri B. Fluoxetine-Induced “Rabbit Syndrome” in a Child With Juvenile Obsessive-Compulsive Disorder. 2022 May-Jun 01Am J Ther. 29(3):e363-e364. [PubMed: 32384313]

28.Edinoff AN, Fort JM, Woo JJ, Causey CD, Burroughs CR, Cornett EM, Kaye AM, Kaye AD. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. Neurol Int. 2021 Sep 01;13(3):445-463. [PMC free article: PMC8482107] [PubMed: 34564289]

29.2021 ACMT Annual Scientific Meeting Abstracts-Virtual. J Med Toxicol. 2021 Mar 31;17(2):93-153. [PMC free article: PMC8011778] [PubMed: 33791944]

30.Wei A, Peng J, Gu Z, Li J. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature. Medicine (Baltimore). 2017 Dec;96(49):e9071. [PMC free article: PMC5728935] [PubMed: 29245320]

31.Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997 Jan-Feb;17(1):170-2. [PubMed: 9017779]

32.Spina E, Barbieri MA, Cicala G, Bruno A, de Leon J. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):31-44. [PubMed: 31795773]

33.de Abajo FJ, Montero D, Rodríguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):304-10. [PubMed: 16611206]

34.Zaccara G, Franco V. Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications. Curr Neuropharmacol. 2023;21(8):1666-1690. [PMC free article: PMC10514545] [PubMed: 35611779]

35.Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract. 2014 Feb;27(1):71-8. [PubMed: 24153222]

36.Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. Case Rep Med. 2016;2016:7128909. [PMC free article: PMC4940515] [PubMed: 27433163]

37.Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139-52. [PMC free article: PMC4860751] [PubMed: 27212965]

38.Selph SS, McDonagh MS. Depression in Children and Adolescents: Evaluation and Treatment. Am Fam Physician. 2019 Nov 15;100(10):609-617. [PubMed: 31730312]

39.Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 05;13(3):387-401. [PMC free article: PMC8395812] [PubMed: 34449705]

40.Riggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2013 Apr;35(4):362-369. [PubMed: 23660045]

41.Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA Psychiatry. 2020 Dec 01;77(12):1246-1255. [PMC free article: PMC7407327] [PubMed: 32777011]

42.Chi SH, Jeong HG, Lee S, Oh SY, Kim SH. Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy. Psychiatry Investig. 2017 Sep;14(5):647-655. [PMC free article: PMC5639133] [PubMed: 29042890]

43.Andrade C. Fluoxetine for Stroke: A Mixed Bag of Outcomes. J Clin Psychiatry. 2021 Jun 08;82(3) [PubMed: 34106530]

44.Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. J Clin Pharm Ther. 2019 Feb;44(1):115-118. [PubMed: 30296343]

45.Akaltun İ, Ayaydin H. Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report. Asia Pac Psychiatry. 2020 Mar;12(1):e12367. [PubMed: 31222962]

46.Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008 Dec;6(4):293-310. [PMC free article: PMC2701282] [PubMed: 19587851]

47.Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. Am J Kidney Dis. 2017 Jan;69(1):87-96. [PubMed: 27773479]

48.Seshadri M, Thalitaya MD, Simon T, Odelola C, Enow H. Antidepressants and Hyponatremia in a patient with Colectomy – a Case Report. Psychiatr Danub. 2017 Sep;29(Suppl 3):610-614. [PubMed: 28953839]

49.Zhang L, Liu X, Li T, Xu B, Fu B. Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study. Neuropsychiatr Dis Treat. 2021;17:3819-3825. [PMC free article: PMC8721155] [PubMed: 35002241]

50.Cooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. Interventions to treat premature ejaculation: a systematic review short report. Health Technol Assess. 2015 Mar;19(21):1-180, v-vi. [PMC free article: PMC4781071] [PubMed: 25768099]

51.Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. Ment Health Clin. 2016 Jul;6(4):191-196. [PMC free article: PMC6007725] [PubMed: 29955469]

52.Lee-Kelland R, Zehra S, Mappa P. Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis. BMJ Case Rep. 2018 Oct 08;2018 [PMC free article: PMC6194370] [PubMed: 30301727]

53.Sharp R. The Hamilton Rating Scale for Depression. Occup Med (Lond). 2015 Jun;65(4):340. [PubMed: 25972613]

54.Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010 Jul-Aug;8(4):348-53. [PMC free article: PMC2906530] [PubMed: 20644190]

55.Beard C, Hsu KJ, Rifkin LS, Busch AB, Björgvinsson T. Validation of the PHQ-9 in a psychiatric sample. J Affect Disord. 2016 Mar 15;193:267-73. [PubMed: 26774513]

56.Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018 Apr;43(3):225-262. [PubMed: 29278603]

57.Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007 May;45(4):315-32. [PubMed: 17486478]

58.Patel DD, Galarneau D. Serotonin Syndrome With Fluoxetine: Two Case Reports. Ochsner J. 2016 Winter;16(4):554-557. [PMC free article: PMC5158166] [PubMed: 27999518]

59.Bruggeman C, O’Day CS. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 4, 2023. Selective Serotonin Reuptake Inhibitor Toxicity. [PubMed: 30521236]

60.Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59 Suppl 15:42-8. [PubMed: 9786310]